YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion. clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metastases
This study looks at combining two existing cancer drugs, YERVOY and OPDIVO, with or without special radiation therapy for people with melanoma that has spread to the brain. It aims to see how well this combination works.
For: melanoma brain metastasesItaly - AuthorisedTherapeutic exploratory (Phase II)
Analysis of the efficacy and safety of two combination treatment regimens of nivolumab and ipilimumab in patients with dMMR and / or MSI metastatic colorectal cancer: A GERCOR open-label, randomized, non-comparative, two-stage phase II trial (NIPISAFE)
This study looks at two types of drug combinations (nivolumab and ipilimumab) for people with advanced bowel cancer that has specific genetic changes (dMMR and/or MSI). It's a Phase II study checking how safe these treatments are and how well they stop the cancer from growing.
For: Patients with DMMR and/or MSI metastatic colorectal cancerFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
This study looks at a new way to treat advanced lung cancer. It compares continuing a combination of two immunotherapy drugs (Nivolumab and Ipilimumab) after initial treatment with simply watching to see what happens. The goal is to find out which approach works better at keeping the cancer from growing.
For: Non small cell lung cancerFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer
This study is testing two new medicines, YERVOY and OPDIVO, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see how well they control the cancer and if they cause any side effects.
For: castration-resistant prostate cancerNetherlands